•  •  Dark Mode

Your Interests & Preferences

I am a...

law firm lawyer
in-house company lawyer
litigation lawyer
law student
aspiring student
other

Website Look & Feel

 •  •  Dark Mode
Blog Layout

Save preferences
Subscribe for perks & to support LI

██████ ██████ retroactively ‘defers’ 15-35% salaries, ██████ promise to take home 0

696 people have already read this article, which will unlock for non-subscribers like you in . So what are you waiting for? Subscribe now!
20 June 2017
Capital Markets

“The Pune Municipal Corporation (PMC) today raised Rs 200 crore by selling 10-year bonds, becoming the first civic body to tap money from this route in 14 years. Proceeds from the issue, raised at a coupon of 7.59 per cent and oversubscribed six times, will be used for a Rs 2,300-crore water project,” reported PTI.

06 June 2017
Capital Markets

The CLIENT:: State Bank of India (SBI);; is planning to raise Rs 15,000 crore in capital through a qualified institutional placement (QIP) of 54.4 crore equity shares, reported Bloomberg Quint.

26 May 2017
Capital Markets

The President of India recently sold 10.19% of shares in HUDCO for Rs 1,209 crores ($188m) in an IPO in India and concurrent private placements outside the country (including a Rule 144A offering in the United States), as reported by The Times of India.

29 March 2017
Capital Markets

Cyril Amarchand Mangaldas acted for Avenue Supermarts on one of the largest (Rs 1800 crore) and most oversubscribed (106 times) initial public offerings (IPOs) ever, alongside Luthra & Luthra and Herbert Smith Freehills Singapore for the banks, listing with a valuation of Rs 39,998 crore - the 67th largest Bombay Stock Exchange-listed company.

07 November 2016
Capital Markets

"The Rs 1,112.50-crore IPO of Varun Beverages was subscribed 1.86 times at a price band of Rs 440-445. The public issue was open during October 26-28.” reported the Economic Times.

04 November 2016
Capital Markets

“State-owned NBCC’s share sale garnered 1.54 times subscription from institutional buyers, who put in bids totalling more than Rs 2,700 crore,” reported the Economic Times.

04 November 2016
Capital Markets

"ECL Finance, a part of the Edelweiss group, has raised Rs 502 crore by selling masala or rupee-denominated bonds to overseas investors in its debut issuance of such securities. Sun Global Investments, London and Emirates NBD Bank, Dubai are the global coordinators and joint lead managers on the transaction,” reported the Economic Times.

06 October 2016
Capital Markets

Squire Patton Boggs and Luthra & Luthra advised Manpasand Beverages on its approximately $80m qualified institutions placement.

03 October 2016
Capital Markets

Cyril Amarchand Mangaldas (CAM) advised ICICI Prudential Life Insurance and ICICI Bank on Rs 60,568 million initial public offer. S&R Associates and Davis Polk & Wardwell advised the lead managers to the issue: DSP Merrill Lynch, ICICI Securities, CLSA India, Deutsche Equities India, Edelweiss Financial Services, HSBC Securities and Capital Markets (India), IIFL, JM Financial Institutional Securities, SBI Capital Markets and UBS Securities India.

08 January 2016
Capital Markets

Cyril Amarchand Mangaldas and Clifford Chance advised book runners Nomura Financial Advisory & Securities (India), Axis Capital, JP Morgan India and Edelweiss Financial Services on the Rs 1,350 crore initial public offer (IPO) of Indian pharma global giant Alkem Laboratories. Alkem was advised by Khaitan & Co.

CAM Mumbai capital markets partner Gaurav Gupte and Clifford Chance Singapore partner Rahul Guptan acted for the four global coordinators and lead managers.

Khaitan Mumbai partner Abhimany Bhattacharya, executive director Sudhir Bassi, principal associate Soumya Mohapatra and associates Aanchal Arora, Aayush Mohata, Abir Sarkar and Srikant Mantravedi acted for Alkem.

The IPO of 12,853,442 Rs 2 equity shares for cash at a price of INR 1,050 per Equity Share, through an offer for sale by the selling shareholders, aggregating to Rs 13,46.62 crore, according to CAM’s press release.

The generic drugs maker had filed its prospectus for the IPO with SEBI in August, reported Business Standard.

The original version of this story overstated the size of the IPO. We regret the error.